company update pt kimia farma tbk · 2020. 10. 23. · speaker mr. pardiman finance director pt...
Post on 15-Dec-2020
6 Views
Preview:
TRANSCRIPT
Healthy Growth Performance
Company Update
PT Kimia Farma Tbk
Q2 – 2020
Speaker
Mr. Pardiman
Finance Director PT Kimia Farma Tbk (KAEF) Indonesian Citizen Education & Training:
Master of Management from Diponegoro University Bachelor of Economics Management from Diponegoro University BUMN Executive Leadership Program IFA Strategic Forum
Employment History:
Finance Director PT Bio Farma (Persero) (2018-2019) Finance Director PT Perum Bulog (2017-2018) Finance Director PT Petrokimia Gresik (2016-2017) President Commisioner PT Kawasan Industri Gresik (2016-2017) Director of Consumer, Micro and Funding PT Bank BRI Syariah (2015-2017)
2
1
2
3
4
MARKET OVERVIEW
COMPANY OVERVIEW
FINANCIAL HIGHLIGHT
BUSINESS EXPANSION & INVESTMENT
Agenda
5 OUR RETAIL BUSINESS-KIMIA FARMA APOTEK
MARKET OVERVIEW
1
Indonesia Pharmaceutical Market (Q2/2020)
Indonesia pharmaceutical market decrease at -1.0% in MAT Q2/2020
Source: IMS IQVIA 2Q/2020
MNC ETHICAL BRANDED,
21.9%
MNC UNBRANDED
GENERIC, 0.1%
DOMESTIC ETHICAL
BRANDED, 30.0%
DOMESTIC UNBRANDED
GENERIC, 17.3%
MNC FREE SALES, 5.2%
DOMESTIC FREE SALES,
25.5%
ETHICAL
69.3%
FREE
SALES
30.7%
In % MAT 2Q19 vs MAT 2Q20 CAGR 4 Y
TOTAL MNC DOMESTIC TOTAL MNC DOMESTIC
TOTAL -1.0 1.7 -1.9 3.9 5.2 3.4
ETHICAL -1.8 0.6 -2.8 4.0 5.4 3.4
ETHICAL BRANDED 1.2 0.9 1.5 3.1 5.6 1.5
UNBRANDED GENERIC -9.8 -33.2 -9.5 6.9 -12.1 7.2
FREE SALES 0.9 6.8 -0.2 3.5 4.1 3.4
16,087 18,017 18,840 18,946
3,836 4,005 4,196 4,481
38,825 41,041
40,782
19,668 21,598
21,983 21,932
8.0
2.8 41,972
-1.0
8
7
6
5
4
3
2
1
0
-1
-2
9
-
20,00
0
10,00
0
50,000
40,000
30,000
60,000
100,000
90,000
80,000
70,000
MAT 2Q17 MAT 2Q19 MAT 2Q20
MNC FREE SALES
DOMESTIC FREE SALES
MAT 2Q18
MNC ETHICAL
DOMESTIC ETHICAL
Growth (%)
• Ethical Branded still growth 1.2% and Free Sales growth 0.9% in MAT Q2/2020, but for the Unbranded Generic decrease -9.8%.
• Unbranded Generic decrease was due to the fact that the budget from Government for Unbranded Generic that should have been spent was diverted to spending on Covid-19 related products, resulting in a fairly high decline.
• This decline can be assumed as a result of the patient paradigm shift from expensive ethical products to BPJS drugs.
-1.0%
-15.2%
MAT Gr QTR Gr
6
Hospital channel has decreased both for MNC and Domestic Company, while in Pharmacy channel, the growth was driven by Domestic Company in MAT Q2 2020.
MAT Q2 2020 VALUE SHARE (PHARMACY, HOSPITAL, DRUGSTORE) – HNA PRICE
43% 43%
65% 65%
33% 32%
26% 27%
5% 5%
32% 35%
24% 22% 30% 30%
26% 24%
7% 8% 0% 0%
9% 9%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
MAT 2Q19 MAT 2Q20
DOMESTIC ETHICAL
MAT 2Q19
DOMESTIC FREE SALES
MAT 2Q20
MNC ETHICAL MNC FREE SALES
Growth
-2.5%
Pharmacy Hospital Drugstore
MAT 2Q19 MAT 2Q20
Channel Value Share in Indonesia (2Q/2020)
Source: IMS IQVIA 2Q/2020
7
0.9% -2.5% -0.5%
COMPANY OVERVIEW
2
Corporate Structure
10
KF : 99.99% KFA: 0.01%
KF : 99.99% YKKKF : 0.01%
KF : 51.00% PTPN VIII: 49.00%
KF : 80.67% SWP : 19.33%
KF : 10.00% Jasindo : 10.00% Bank Mandiri : 80.00% (Equity Capital)
KF : 60.00% MBM : 40.00%
2003 2003 2011 2014 2018 2016
KFA : 99.99% YKKKF: 0.01%
2019
KF : 56.77% Public : 43.23%
Lucas: 99.91% Others: 0.09%
PEHA : 20.00% Others: 80.00%
PEHA: 90.25% Others: 9.75%
* December 31, 2019
Government 9.975%
Public 90.025% 90.025%
PT Bio Farma (Persero)
1 Share Seri A Dwiwarna Government
9.975% Public
* June 30, 2020
Top 20 Pharmaceutical Industry in Indonesia (2Q/2020)
MAT Rank Top 20 Companies Share% Growth%
1 5.9 -5.5
2 5.7 -4.1
3 4.9 -17.0
4 3.0 -4.0
5 2.8 0.1 6 2.4 -18.9
7 2.2 13.8
8 2.1 -3.1
9 2.1 52.5
10 2.0 9.4
11 1.9 -1.8
12 1.9 -7.5
13 1.9 -0.9
14 1.9 5.1
15 1.8 -21.7
16 1.8 13.4
17 1.6 -9.5
18 1.6 -0.3 19 1.6 -20.8
20 1.5 -4.2
+ 1,133 (2.8%)
315 (0.8%)
1,448 (3.6%)
Source: Indonesia Total Market Q2 2020
+ +
628 (1.6%)
1,448 (3.6%)
185 (0.5%)
2,261 (5.7%)
HOLDING BUMN FARMASI
605
628
628
633
710
736
751
753
761
773
797
834
854
892
980
1.133
1.190
1.956
2.305
2.374
PFIZER
DANKOS
BIOFARMA
B.INGELHEIM
DJOJONEGORO C-1000
INTERBAT
ASTRAZENECA
FAHRENHEIT
FERRON PAR PHARM
SANOFI-AVENTIS
BAYER INDONESIA
SOHO
LAPI
DARYA VARIA
NOVARTIS
KIMIA FARMA
NOVELL PHARM
KALBE FARMA
SANBE
DEXA MEDICA
3
4
11
1,133
1,190
1,956
2,305
,374
Integrated Business Chain
Manufacture of
Active Pharmaceutical
Ingredients (API)
Production
Facility
National
Distribution Center
(NDC)
Retail Pharmacy Trading &
Distribution
Clinic & Clinical
Laboratory Customer
Unit Usaha
Business Unit
Sumatera,
Batam Jawa
Bali, Nusa
Tenggara Kalimantan
Sulawesi,
Maluku, Papua Total
Plant 1 10 1 12
Distributor 11 21 3 5 9 49
Retail Pharmacy 217 667 121 130 173 1,308
Clinical Laboratory 11 42 3 6 8 70
Clinic 65 272 24 56 69 486
*June 30, 2020
12
Company Products & Composition Q2/2020
13
OTC & Herbal 8.50%
Cosmetics 15.29%
Generics 47.29%
Ethical 23.18%
API 4.74%
Export 1.00%
Medical Devices 0.00%
OTC & Herbal Ethical
Generic API Medical Device
Cosmetics
OTC & Herbal 10.99%
Cosmetics 7.77%
Generic 49.56%
Ethical 20.94%
API 2.81% Export
0.81%
Medical Devices 7.13%
Q2/2020
Q2/2019
Covid–19 Health and Safety Audits
STAKEHOLDERS
COVID-19 will change business even after the pandemic ends and it is unlikely that everything will return to “NORMAL“ and
now we are entering the “NEW NORMAL” era.
Business will face signifcant calllenges in protecting the “SAFE GUARD Employee and Stakeholders of the Company
from the health and safety risk associated with the spread of COVID-19.
So that the Company must be able to protect and build trust with Employees and Stakeholders, as a form of
transparency and credibility to the Public and Stakeholders.
Currently, the Company is preparing to conduct a Health and Safety Audit related to COVID-19.
18
Certification
Good Manufacturing Practice Plant Watudakon, Medan, Bandung, Jakarta
Good Distribution Practice (GDP) Trading & Distribution
Food Safety System Certification (FSSC) 22000 Plant Kina (SIL)
Halal MUI Certificate Plant Bandung, Semarang, Watudakon, Plant Kina (SIL)
Good Traditional Medicine Manufacturing Practice Plant Bandung, Jakarta
ISO 9001: 2008 Plant Jakarta, Bandung, Watudakon, Medan
Certificate of Suitablity Plant Kina (SIL)
Kosher Certificate Plant Kina (SIL)
Good API Manufacturing Practice Plant Kina (SIL)
ISO 9001: 2015 Plant Semarang, Plant Kina (SIL)
ISO 14001: 2015 Plant Watudakon
Green Environment Certificate Plant Jakarta, Bandung, Watudakon, Medan
20
Award
Top Brand Award
Itech Top Digital Innovation Transformation in Smart Healthcare Business 2019
BUMN Marketers Award The most promising company in tactical
market 2019 The most promising company in strategic
marketing 2019 The most promising company in market
3.0 2019
Musium Rekor Indonesia
(MURI)
CSR
Kimia Farma Apotek Digital Popular Brand Award
The Best Corporate Philantropy for Apung Clinic
Indonesia Best Corporate
Sustainability Initiatives
TOP 50 Company Corporate
Governance Award 2019
IICD Corporate
Governance Award
Indonesia Employers of
Choice Award 2019 The Winner of Indonesian Employers Of
Choice Award 2019 The Winner of Job Seeker by Korn Ferry
2019
Investor Award
HR Excellent Award
2020
Top CSR Award 2020
3 Awards from Top Brand for: Enkasari (Sprue Medicine), Salycil (Health Powder), Asifit products (the category of Breast Milk Booster)
The most of the use of mouthwash with participants simultaneously
Best BUMN 2019 in the category of Non-Financial, Pharmaceutical, Food and Miscellaneous Industries
Winner of the HR Excellence Award, in Category: HR Transformation, with a grade: A from SWA magazine
The best CSR in the pharmaceutical industry. Excellent Program for Local Community Development
Top CSR Award Star # 4 from Top Business, the National Committee on Governance Policy, and the Nawacita Research Institute
21
Long Term Plan Strategy 2020 – 2024
Retail Transformation Supply Chain
Optimization Increase the diversity
of products and portfolios through strategic alliances
Manufacturing Excellence & Digital Initiative
Stabilization and realization of synergies by acquisitions
Addition of BBO Factory Facilities
Commercialization of BBO products
The Banjaran factory is fully operational
Marketing and positioning of existing brands
Additional capacity and products at KFSP
BBO Import reduction Optimization of the
Banjaran Factory Realization of digital
potential throughout the value chain (joint collaboration with digital partners)
Exporter of high value BBO and essential oils
Household name for health and beauty herbal products
Becoming one of the most popular workplaces in Indonesia
The leading choice as an integrated healthcare provider
• Global network and product expansion
2020
2021
2022
2023
2024
22
With a complete business portfolio (end to end) Kimia Farma is committed to creating integrated health services
INTEGRATED HEALTHCARE ECOSYSTEM
1
2
3
4
5 One of the Company's strategies is to conduct a strategic alliance, this strategy is expected to be able to add to the Company's value proposition to complete the healthcare business portfolio
INORGANIC GROWTH
To strengthen the Company's core business, efforts and strategic approaches are carried out in running the business lines
PORTFOLIO OPTIMIZATION
The initiative is in line with the transformation strategy carried out by the Company, the focus for this is: retail transformation, marketing leadership, penetration of modern markets and strategic relationship management
COMMERCIAL EXCELLENCE
Strengthening the entire value chain business in Kimia Farma Group with its main goal is that the process can run more effectively and efficiently
OPERATIONAL EXCELLENCE
Strategic Initiatives 2020
23
FINANCIAL HIGHLIGHTS
3
Peer Performance Q2/2020
5,44
38,05
26,11
3,60
3,10
-1,50
6,70
-1,00 -5,00
0,00
5,00
10,00
15,00
20,00
25,00
30,00
35,00
40,00
45,00
2017 2018 2019 Q2/2020
KIMIA FARMA 5.44 38.05 26.11 3.60
PHARMACY INDUSTRY 3.10 -1.50 6.70 -1.00
25
KAEF KLBF TSPC DVLA MERK SIDO PYFA PEHA INAF
Growth 3,6 3,81 -0,11 1,56 -10,72 3,52 0,17 -17,78 21,28
3,60 3,81
-0,11
1,56
-10,72
3,52 0,17
-17,78
21,28
-20,00
-15,00
-10,00
-5,00
-
5,00
10,00
15,00
20,00
25,00
Peers Growth (2Q/2020)
7.888.135
6.932.831
Q2 2019 Q2 2020
8.909.395
10.581.168
Q2 2019 Q2 2020
16.797.529
17.513.999
Q2 2019 Q2 2020
394.502
496.729
Q2 2019 Q2 2020
296.302
365.034
Q2 2019 Q2 2020
4.524.819
4.687.803
Q2 2019 Q2 2020
REVENUE OPERATING PROFIT
3.60%
23.20%
ASSETS LIABILITIES EQUITY
4.27% 18.76% 12.11%
In IDR billion
EBITDA
25.91%
In IDR billion In IDR billion
In IDR billion In IDR billion In IDR billion
Financial Performance Q2/2020
Note: the decline in equity comes from the implementation of PSAK 71 forcing the company to preserve OCI
26
4,524,819
4,687,803 296,302
365,034
394,502
496,729
16,797,529
17,513,999
8,909,395
10,581,168 7,888,135
6,932,831
EBITDA MARGIN ROI
ROA
Financial Performance Q2/2020
ROE
8,72%
10,60%
Q2 2019 Q2 2020
1,93%
2,14%
Q2 2019 Q2 2020
0,28% 0,28%
Q2 2019 Q2 2020
0,85%
0,68%
Q2 2019 Q2 2020
27
8.72%
10.60%
1.93%
2.14%
0.85%
0.68%
0.28% 0.28%
BUSINESS EXPANSION & INVESTMENT
4
Business Expansion & Investment
4,826 Billion
Banjaran Plant Rapid Test Plant API & HFC Plant
Kimia Farma Dawaa (Saudi Arabia)
Pharmacy, Clinics & Clinical Lab
Health & Beauty Clinic
Acquisition of PT Phapros Tbk
Injection Prod. Facility
Retail Pharmacy Digitalization
SAP, QR Code, Track & Trace, and
Internet of Things (IoT)
Distribution (KFTD) Renovation
In IDR Billion
788
1.352
2.140
546
2017 2018 2019 2020
CAPEX 2017 - 2020
*
*projection 2020
30
1,352
2,140
OUR RETAIL BUSINESS-KIMIA FARMA APOTEK
5
Integrated Healthcare Network
Services Sumatera Jawa Kalimantan Bali ,Nusa Tenggara
Sulawesi, Maluku, Papua
Total
APOTEKS 217 667 130 121 173 1,308
HEALTH CLINICS
65 272 56 24 69 486
BEAUTY CLINICS
3 3
CLINICAL LABORATORIES
11 42 6 3 8 70
OPTICS 2 8 10
Kimia Farma Apotek has a fully integrated, seamless healthcare network covering all 34 provinces in Indonesia – cementing its position as the biggest upstream-downstream pharmacy player in Indonesia
33
Kimia Farma Apotek – Our Retail Side
HISTORY
OUR SERVICES
No. of employees
> 9000
OUR PRODUCTS
70 Outlet di 34 kota besar dan 10- outlet optik
34
• 1.308 Pharmacy • Standard Good Pharmacy Practice (GPP) • More than 38.000 SKU (ethical, OTC,
Medical Device) • Outblets in Airport, Hotel, and Mall
• 468 Klinik Pratama & Utama • Clinic Managed Care • BPJS Network Provider (open
provider) • Vaccination Services with
International Certified • Dental clinic service • Haemodialysis clinic
980.336
807.776
Q2 2019 Q2 2020
2.050.416
2.380.664
Q2 2019 Q2 2020
3.030.752
3.188.440
Q2 2019 Q2 2020
91.405
225.789
Q2 2019 Q2 2020
76.010
105.669
Q2 2019 Q2 2020
2.411.928
2.723.725
Q2 2019 Q2 2020
REVENUE OPERATING PROFIT
12.93% 39.20%
ASSETS LIABILITIES EQUITY
5.20% 16.11% 17.60%
In IDR billion
EBITDA
147.02%
In IDR billion In IDR billion
In IDR billion In IDR billion In IDR billion
Financial Performance Q2/2020
Note: the decline in equity comes from the implementation of PSAK 71 forcing the company to preserve OCI
35
2,411,928
2,723,725
3,030,752
76,010
105,669
2,050,416
2,380,664
91,405
225,789
980,336 3,188,440
807,776
1,27%
1,46%
Q2 2019 Q2 2020
5,02% 5,07%
Q2 2019 Q2 2020
2,54%
3,36%
Q2 2019 Q2 2020
3,79%
8,29%
Q2 2019 Q2 2020
EBITDA MARGIN ROI
ROA
Financial Performance Q2/2020
ROE
36
3.79%
8.29%
2.54%
5.02% 5.07%
1.27%
1.46%
3.36%
Kimia Farma Apotek - Digital Development Roadmap 2020
Digitization to accelerate
and optimize business
Pulverizing
2022
Scaling up business growth through
customer experience approach
Watering 2023
Transform, manage, boost and
enrich KFA business portfolio
Fertilizing 2024
Subsidiarizing and Going Beyond
Harvesting
2021
Explore new business models and
revenue streams enhancement
Seeding
1. Launching - Kimia Farma Mobile: Ethical, OTC, Prescription drugs, vaccine reservation
2. Integrated 7 Solutions platform with all KFA Services: Smartstock, OmniChannel, Customer Loyalty, Big Data Analytics, Clinic Integration, BPJS PRB, Homecare
3. SEO Location: Location tagging optimization for all 1266 outlets in Google My Business (GMB)
1. 7 Solutions Optimization: Clinic Optimization, Strategic partnership for healthcare ecosystem (Insurance, SEO, Hospital, etc), BUMN Connectivity, Customer Loyalty & Membership
2. Telemedicine: comprehensive tech-based long distance service by healthcare professionals (examination, consultation, diagnosis, prescription, references)
3. New Business Model • KF Digital Experience Store • KFPort, Virtual Store in strategic
public space • KFAds: Monetize Display Asset for
both Physical and Digital signage 3rd party advertising
4. SEO Location: Monetizing GMB location to 3rd party principals
5. Integrated Social Media
1. Kimia Farma Mobile as a Healthcare hub: a super app covering all of Indonesia healthcare ecosystem.
2. Big Data Monetizing business insight from the healthcare ecosystem data
1. New Customer Acquisition: 100,000
1. New Customer acquisition: 1 million
2. Physician collaboration: 1,000 affiliated MDs
1. New customer acquisition: 4 million
2. Physician collaboration: 2,000 external MDs, 500 specialists
1. New customer acquisition: 6 million 2. Physician collaboration: 1,500 MDs,
200 specialists 3. Healthcare hub: 2,000 3rd party
pharmacies
1. New customer acquisition: 8 million
2. Revenue: 940 billion
1. 7 Solutions Exploration: business process efficiency, other income optimization, new business model
2. Increasing Omni-Channel scale with Big Data Analysis
3. KF Mobile feature enhancement: • Augmented Reality (AR) Beauty, Optic • AI Machine Learning for prediction
analysis and personalized service • New Features: Mother & Child,
Wellness & Nutrition, Sexual Health 4. Telemedicine optimization 5. KF Mobile service building: new
customer acquisition, specialist doctor collaboration
6. 7Solutions: SAAS (Software As A Service) business model
7. Single-ID Customer Loyalty 8. GMB growth to all new outlets 9. KF Ads and KF Port growth to 2 times
of 2021
1. KFAds Subsidiary 2. KFPort Subsidiary 3. KFMobile Subsidiary
37
On average: 91,000 transactions per day
• Integrated inventory • Forecasting • Integrated master data
Smartstock
• 34 provinces of Indonesia • 1,318 outlets (pharmacies & optics) • 486 clinics (managed by KFD) • 70 laboratories (managed by KFD) • 3 beauty clinics • Online channels: 1,254 pharmacies • Integrated with BPJS-PCare: 9 clinics • Integrated with BPJS-Apotekonline: 5 pharmacies • Homecare dokter: 3 clinics • Home Pharmacy Care: 5 pharmacies
Outlets: • POS for pharmacies • Sistem Klinik • Laboratory Information
System (LIS)
Kimia Farma Online: • e-Commerce • Clinic reservation • Online consultation • PRB Community
• BPJS-Pcare • BPJS-apotekonline
*)
*) *)
*) to-be
• Insurance/TPA
• Cashless payment
• Delivery
Partners:
API
• Potensi lainnya Affiliated physicians
Hospital pharmacy installations e-klinik PCMI
Kimia Farma Apotek Digitalization
Appstore (IoS): 4.9 , 692 reviews, 2,573
downloads
Playstore (Android): 5.0 , 5,174 reviews, 31,600
downloads
38
More than just a health app, Kimia Farma Mobile is our new platform for a healthy lifestyle –
easily, quickly, and above all, digitally.
2,573 download
31,600 downloads
As a Integrated Healthcare SOE, we keep transforming our service quality; in 16 August 2020, we launched Kimia Farma Mobile, our mobile app services – accessible anywhere and anytime
OMNI Channel Connected with our 1254
pharmacies, all across Indonesia
Complete Payment Options CC, Virtual Account, eWallet
Various Shipping Options Gosend, JNE, GrabExpress,
Kimia Farma Delivery
Ease of Access Anytime, Anywhere
Homecare Kimia Farma quality healthcare,
right at your doorstep
Vaccine Reservation Online vaccine services
Diagnostic Services Our integrated clinical laboratory
and healthcare clinic services
Online Consultation With our top pharmacists &
physicians
Kimia Farma Mobile
Top Trending Search for Medical Category App (15-Okt) in Playstore
Top GoogleSearch for “beli obat online” keyword
(15-Okt)
by October 11th, 2020
40
Kimia Farma Drive-Thru
Our new breakthrough – the first EVER drive thru pharmacy in Indonesia
Where? Apotek Kimia Farma 11 Supratman Bandung Jl. Supratman NO. 72, Kota Bandung.
Why? 1. To combat the COVID-19 pandemic by helping people
follow the strict healthcare protocol for physical distancing
2. To give a feeling of safety and comfort for our customers in getting their healthcare needs
3. To create a brand new customer experience
What? Directly buy OTC and prescription drugs, medical devices, food supplements and more from your vehicle without having to get down from your car – teleconsultation with our top qualified pharmacist as you drive by.
41
Kimia Farma and the COVID-19 Pandemic: Mobile Lab PCR
Kimia Farma Diagnostika will expand the reach of our COVID-19 PCR test to even more people and more area in Indonesia, by making it mobile. By the end of 2020, five PCR Mobile Lab Unit will be opened in 5 cities: Surabaya, Denpasar, Banjarmasin, Batam, Jakarta
1. Mobile Unit + Modified Hino Dutro Cabin Long Chasis, Sandwich Panel & Lab Instruments
2. Supporting Instruments 3. Comparative Test 4. Operational
Mobile Lab PCR spec and steps:
42
Kimia Farma for Indonesia
Kimia Farma gained public trust as
the most comprehensive and
largest health service provider in
Indonesia with its business chain
from the upstream to the
downstream of the industry for more
than 49 years.
Non-Stop Dedication
Kimia Farma supports
the availability of drugs and health products
to each and every
region in Indonesia
Equality In Health Distribution
In achieving a Healthy Indonesia, Kimia
Farma conducts research and development, as well
as innovates to produce good quality products, some
of which are the Covid-19 treatment drug
(Chloroquine, Hydroxychloroquine, Azithromycin,
Favipiravir, Covid – 19 Rapid Test, Immunomodulator)
Keep Inovating
Supporting the Government as the
only pharmaceutical industry that
produces HIV Medicines
Real Action For Indonesia
Kimia Farma through its Subsidiary, Kimia Farma
Apotek (KFA) and Kimia Farma Diagnostika (KFD)
reaches all over the country.
Complete and Integrated Health Services
With the facility of Active
Pharmaceutical Ingredients (API)
Kimia Farma encourages the
creation of API in Indonesia in
accordance with the ideals of
Indonesia
National Independence
As a Healthcare Solution,
Kimia Farma always provides comfort
and a different experience. Through
Kimia Farma Mobile Apps and Kimia
Farma Drive Thru, as one of the
solutions for digital customer
experiences
Costumer Focus
44
KANTOR PUSAT
Jl. Veteran No. 9 Jakarta Pusat 10110 Phone: +62 21 3847709 | Fax: +62 21 3814441
Email: corsec@kimiafarma.co.id Website: www.kimiafarma.co.id
Terima Kasih
Semoga Sehat Selalu
top related